Literature DB >> 8794337

Cooperation between herpes simplex virus type 1-encoded ICP0 and Tat to support transcription of human immunodeficiency virus type 1 long terminal repeat in vivo can occur in the absence of the TAR binding site.

S L Schafer1, J Vlach, P M Pitha.   

Abstract

Expression of human immunodeficiency virus type 1 (HIV-1) provirus can be stimulated by herpes simplex virus type 1 (HSV-1) infection; the stimulation occurs at the level of transcriptional activation of the HIV long terminal repeat (LTR) and is mediated by both cellular and HSV-1-encoded transactivators. We have shown in this study that HSV-1 immediate-early gene ICP0 cooperates effectively with the HIV-1-encoded transactivator, Tat, in the stimulation of HIV-1 LTR-directed transcription. The cooperation between ICP0 and Tat is specific for the HIV-1 LTR and was not observed with other promoters (e.g., ICP0) that can be transactivated by ICP0 but not by Tat. Analyses of HIV-1 LTR deletion mutants have shown that ICP0 not only transactivates an HIV-1 LTR mutant that is unresponsive to NF-kappaB and Tat-mediated transactivation, such as the HIV-1 LTR with the enhancer deleted (-83 LTR) and TAR deleted (+20 to +81), but also restores responsiveness to Tat. ICP0 also showed cooperation with Gal4-Tat fusion protein-mediated transactivation of Gal4-HIV-1 LTR with TAR deleted. Enhancement of the transcriptional activation of ICP0 by Tat requires both the cysteine-rich and core domains of Tat and is inhibited by RO5-3335. ICP0 stimulates transcription of not only the HIV-1 LTR but also the TAR-defective HIV-1 provirus. We suggest that ICP0 can (i) recruit Tat to the vicinity of the HIV-1 promoter, thereby providing an alternative binding site for Tat, and (ii) substitute for the enhancer-binding proteins that are required for efficient Tat transactivation in T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794337      PMCID: PMC190743     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  90 in total

1.  tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185.

Authors:  F Wu; J Garcia; D Sigman; R Gaynor
Journal:  Genes Dev       Date:  1991-11       Impact factor: 11.361

2.  A recombinant HIV provirus is synergistically activated by the HIV Tat protein and the HSV IE1 protein but not by the HSV IE3 protein.

Authors:  C J Chapman; J D Harris; M K Collins; D S Latchman
Journal:  AIDS       Date:  1991-08       Impact factor: 4.177

3.  Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat.

Authors:  B Berkhout; K T Jeang
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Tumor necrosis factor stimulates transcription of HIV-1 in human T lymphocytes, independently and synergistically with mitogens.

Authors:  N Israël; U Hazan; J Alcami; A Munier; F Arenzana-Seisdedos; F Bachelerie; A Israël; J L Virelizier
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

5.  Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation.

Authors:  M F Laspia; A P Rice; M B Mathews
Journal:  Genes Dev       Date:  1990-12       Impact factor: 11.361

6.  Direct interaction of human TFIID with the HIV-1 transactivator tat.

Authors:  F Kashanchi; G Piras; M F Radonovich; J F Duvall; A Fattaey; C M Chiang; R G Roeder; J N Brady
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

7.  TAR-independent transactivation of the murine cytomegalovirus major immediate-early promoter by the Tat protein.

Authors:  Y S Kim; R Risser
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

8.  TAR-independent replication of human immunodeficiency virus type 1 in glial cells.

Authors:  O Bagasra; K Khalili; T Seshamma; J P Taylor; R J Pomerantz
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs.

Authors:  S J Arrigo; I S Chen
Journal:  Genes Dev       Date:  1991-05       Impact factor: 11.361

10.  TAR-independent transactivation by Tat in cells derived from the CNS: a novel mechanism of HIV-1 gene regulation.

Authors:  J P Taylor; R Pomerantz; O Bagasra; M Chowdhury; J Rappaport; K Khalili; S Amini
Journal:  EMBO J       Date:  1992-09       Impact factor: 11.598

View more
  5 in total

Review 1.  Molecular pathways in virus-induced cytokine production.

Authors:  T H Mogensen; S R Paludan
Journal:  Microbiol Mol Biol Rev       Date:  2001-03       Impact factor: 11.056

2.  Analysis of Select Herpes Simplex Virus 1 (HSV-1) Proteins for Restriction of Human Immunodeficiency Virus Type 1 (HIV-1): HSV-1 gM Protein Potently Restricts HIV-1 by Preventing Intracellular Transport and Processing of Env gp160.

Authors:  Sachith Polpitiya Arachchige; Wyatt Henke; Ankita Pramanik; Maria Kalamvoki; Edward B Stephens
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

3.  Herpes simplex virus type 2 triggers reactivation of Kaposi's sarcoma-associated herpesvirus from latency and collaborates with HIV-1 Tat.

Authors:  Qiao Tang; Di Qin; Zhigang Lv; Xiaolei Zhu; Xinting Ma; Qin Yan; Yi Zeng; Yuanyuan Guo; Ninghan Feng; Chun Lu
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

4.  The CD8 antiviral factor (CAF) can suppress HIV-1 transcription from the long terminal repeat (LTR) promoter in the absence of elements upstream of the CATATAA box.

Authors:  Varsha Shridhar; Yue Chen; Phalguni Gupta
Journal:  Virol J       Date:  2014-07-21       Impact factor: 4.099

5.  Altered HIV-1 Viral Copy Number and Gene Expression Profiles of Peripheral (CEM CCR5+) and Mucosal (A3R5.7) T Cell Lines Co-Infected with HSV-2 In Vitro.

Authors:  Dipen Desai; Rajkumar Londhe; Madhuri Chandane; Smita Kulkarni
Journal:  Viruses       Date:  2022-08-04       Impact factor: 5.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.